Analysts Set uniQure N.V. (NASDAQ:QURE) PT at $58.33

Shares of uniQure N.V. (NASDAQ:QURE) have been given a consensus recommendation of “Moderate Buy” by the fourteen brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $58.3333.

A number of research firms have recently weighed in on QURE. Leerink Partners cut their price target on uniQure from $68.00 to $60.00 and set an “outperform” rating for the company in a research note on Monday, November 10th. Wells Fargo & Company dropped their price objective on uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, November 12th. The Goldman Sachs Group reduced their target price on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research note on Tuesday, November 4th. Barclays began coverage on shares of uniQure in a research report on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 target price for the company. Finally, Royal Bank Of Canada cut their price target on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a report on Monday, November 3rd.

Insider Activity

In other uniQure news, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the sale, the director owned 32,342 shares of the company’s stock, valued at $796,260.04. The trade was a 44.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jack Kaye sold 6,390 shares of the stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the transaction, the director directly owned 20,439 shares in the company, valued at approximately $557,575.92. This represents a 23.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.79% of the stock is owned by company insiders.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently modified their holdings of QURE. Jefferies Financial Group Inc. acquired a new position in uniQure in the 2nd quarter valued at $29,217,000. State Street Corp lifted its position in uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after acquiring an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the period. Fred Alger Management LLC acquired a new stake in shares of uniQure in the third quarter valued at about $75,320,000. Finally, Sofinnova Investments Inc. grew its position in shares of uniQure by 185.5% in the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock valued at $21,723,000 after purchasing an additional 1,012,585 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on uniQure, which may provide some analyst support for the stock. Read More.
• Positive Sentiment: Aggregate analyst coverage shows a consensus “Moderate Buy” on QURE, a signal that some sell‑side analysts still view upside. Read More.
• Neutral Sentiment: Profile/feature mentions (e.g., a Time piece listed in feeds) appear unrelated to the securities actions and are unlikely to move the stock materially. Read More.
• Negative Sentiment: Multiple law firms have filed or announced securities‑class actions and investor alerts against uniQure alleging violations of federal securities laws for the period Sept. 24, 2025–Oct. 31, 2025 — several firms (Schall, Rosen, Berger Montague, Kessler Topaz, DJS, Faruqi, Bernstein Liebhard, ClaimsFiler, etc.) are soliciting lead‑plaintiff applications and investigations. This wave of litigation increases legal risk, potential damages, and investor uncertainty. Read More. Read More. Read More.
• Negative Sentiment: At least one notice and media summary links the litigation to an alleged FDA approval delay and a roughly 49% prior stock decline; such factual allegations (if pursued) could prolong volatility, increase settlement risk, and weigh on investor sentiment. Read More.

uniQure Trading Down 8.4%

uniQure stock opened at $20.50 on Friday. uniQure has a 12 month low of $7.76 and a 12 month high of $71.50. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The stock has a market cap of $1.28 billion, a P/E ratio of -4.67 and a beta of 0.66. The company’s fifty day simple moving average is $23.37 and its 200-day simple moving average is $29.23.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.